Proton pump inhibitors (PPIs) are among the most frequently prescribed medications. Their
use is likely even higher than estimated due to an increase in the number of PPIs available …

OBJECTIVEAn estimated 20–30% of patients with primary Clostridium difficile infection
(CDI) develop recurrent CDI (rCDI) within 2 weeks of completion of therapy. While the actual …

Abstract Scope In 2009, the European Society of Clinical Microbiology and Infectious
Diseases (ESCMID) published the first treatment guidance document for Clostridioides …

Background Proton pump inhibitor (PPI) therapy is a potentially modifiable risk factor for
recurrent Clostridioides difficile infection (CDI). Citing an absence of clinical trials, many …

Objectives Clostridioides difficile infection (CDI), its subsequent recurrences (rCDIs), and
severe CDI (sCDI) provide a significant burden for both patients and the healthcare system …

Background Clostridium difficile infection (CDI) is a cause of increased morbidity and health
care costs among hospitalized patients. Proton pump inhibitors (PPIs) are mainly used for …

Background Clostridium difficile is the main cause of hospital-acquired diarrhea and colitis
known as C. difficile-associated disease (CDAD). With increased severity and failure of …

Introduction Clostridioides difficile infection (CDI) is the main cause of nosocomial diarrhoea
in developed countries. Recurrent CDI (R-CDI), which affects 20%-30% of patients and …

Over the past two decades Clostridium difficile infection (CDI) has appeared as a major
public health threat. We performed a retrospective study based on the records of patients …

Частота и смертность от Clostridium difficile-инфекции (КДИ) за последние 10-20 лет
значительно возросла. КДИ является ведущей причиной антибиотик-ассоциированной …